Bleomycin (NSC-125066) therapy of responsive solid tumors.

Area of Science:

• Oncology
• Pharmacology

Background:

• Bleomycin is an antineoplastic agent used in treating various cancers.
• The optimal route of administration for bleomycin in advanced head and neck and testicular carcinomas requires further investigation.

Purpose of the Study:

• To compare the efficacy and toxicity of intravenous (i.v.) versus intramuscular (i.m.) bleomycin in patients with advanced head and neck squamous cell carcinoma or testicular carcinoma.

Main Methods:

• A randomized trial involving 110 patients with far advanced head and neck squamous cell carcinoma or testicular carcinoma.
• Patients were assigned to receive bleomycin via i.v. or i.m. injection.
• Response rates and toxicity were assessed for both administration routes.

Main Results:

• Overall response rates were 6.2% for head and neck squamous cell carcinoma (i.m. 8%, i.v. 5%) and 14% for testicular tumors (i.m. 29%, i.v. 0%).
• While i.m. administration showed a higher response rate in testicular cancer patients, the difference was not statistically significant across all patient groups.
• Toxicity associated with bleomycin was generally manageable.

Conclusions:

• Intramuscular bleomycin may offer a potential benefit for testicular carcinoma treatment, warranting further research.
• Bleomycin administration routes should be considered based on tumor type and potential efficacy.
• Further studies are needed to confirm the superiority of i.m. over i.v. bleomycin in specific advanced carcinomas.